Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% basliginda one cikan gelisme: The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.